
AstraZeneca’s October 15 collaboration with insitro offers a useful look at how a buyer and a specialist partner can divide payment across the life of a high-risk project.
The announced terms include a $40 million upfront payment, eligibility for up to approximately $1.46 billion in potential discovery, development, and commercial milestone payments, and potential single-digit royalties based on global sales. AstraZeneca will have exclusive worldwide rights to advance selected programs identified through the collaboration. The milestone amount is contingent, and royalties depend on products reaching the market and generating sales. The headline value should not be read as guaranteed revenue for insitro. (astrazeneca.com)
Three layers of compensation
The agreement combines three types of payment, each attached to a different point in the work and risk.
1. Upfront compensation funds the work
The $40 million upfront payment gives the collaboration immediate economic value. It recognizes the capabilities and work brought into the partnership while providing funding before the long path from discovery to commercial sales is known.
In this case, insitro applies its Virtual Human platform to identify causal disease biology and advance AstraZeneca-nominated targets from discovery toward development candidates. AstraZeneca leads clinical development, regulatory work, and commercialization. (insitro.com)
That division matters. The upfront amount is not merely an hourly fee. It sits within an agreement covering specialized capabilities, research activity, and rights to pursue selected programs.
2. Milestones tie payment to defined progress
The potential milestone payments connect additional compensation to future discovery, development, and commercial achievements. In principle, a milestone makes payment depend on an agreed event rather than time spent.
But a milestone is only useful if the parties define it clearly. The contract needs to say what qualifies, who verifies it, what evidence is required, when payment is due, and what happens if the project changes direction. Otherwise, “pay for progress” can turn into a dispute over what progress means.
Milestones also create a way to share risk. The specialist partner may earn more if programs advance, while the buyer avoids paying the entire potential value before results are known. The partner, in turn, accepts that some of the potential compensation may never be earned.
3. Royalties connect compensation to commercial performance
Potential royalties add a longer-term layer: if a resulting medicine is commercialized and produces sales, insitro may receive a share. That is different from a payment for completing a research task. It ties future compensation to commercial performance.
Royalties also carry more uncertainty. A program must survive scientific, clinical, regulatory, and commercial hurdles before sales exist. The deal therefore places some potential upside far into the future, where outcomes are uncertain and the value of future payments differs from cash received today.
The value is in the partnership, not just the AI
It would be easy to describe this as a company licensing AI and another company paying for it. That misses the broader arrangement.
The announced collaboration combines insitro’s AI-enabled biological discovery work with AstraZeneca’s clinical development, regulatory, and commercialization capabilities. It also grants AstraZeneca exclusive worldwide rights to advance selected programs. The commercial structure reflects an exchange of capabilities, work, rights, and risk—not simply access to a model. (astrazeneca.com)
That distinction is important for businesses selling AI-enabled expertise. Buyers rarely pay a premium just because AI was used. They pay when the work helps solve a consequential problem, produces evidence they can evaluate, and fits into a process that can turn the work into business value.
What entrepreneurs can take from the deal
Most consulting firms should not copy a pharmaceutical deal’s royalties or long development timeline. The transferable idea is to build a pricing structure that matches compensation to the work and the outcome.
A business could combine:
- A base fee for discovery, setup, access, or reserved capacity.
- Milestone payments for defined and accepted outputs, such as a validated workflow, completed implementation, or measurable quality threshold.
- A success fee or revenue share when the result can be measured and the provider’s contribution is clear.
This structure should also protect both sides. Define the baseline, measurement method, data source, acceptance criteria, payment trigger, time period, and responsibilities. Address what happens when the client changes scope, delays implementation, or controls an important part of the result. Keep guaranteed compensation sufficient to fund the work, especially when results depend on external factors.
Outcome-based pricing is not “charge more if the client gets lucky.” It is a deliberate agreement about what value means, what evidence will prove it, and how the parties will share uncertainty.
The AstraZeneca–insitro deal makes that structure visible: some compensation is paid upfront, more may follow verified milestones, and additional upside may depend on commercial success. The headline amount captures the maximum potential under the agreement. The actual economics depend on what gets achieved.
Entrepreneur question: Which part of your expertise could be priced around verified progress or results instead of hours alone?



